In Psoriasis Lesional Skin the Type I Interferon Signaling Pathway Is Activated, whereas Interferon-α Sensitivity Is Unaltered

Journal of Investigative Dermatology

Volumn 122, Issue 1, 2004, Pages 51-60

  Van Der Fits, Leslie ^a   Van Der Wel, Leontine I ^a   Laman, Jon D ^a   Prens, Errol P ^a   Verschuren, Martie C M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Inflammation; Interferon regulatory factor; Interferon ; Keratinocytes

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON REGULATORY FACTOR 1; RECOMBINANT ALPHA INTERFERON;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; MECHANOTRANSDUCTION; MEDICAL ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS VULGARIS; SKIN BIOPSY; SKIN DEFECT; SKIN SENSITIVITY;

EID: 1642493842     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0022-202X.2003.22113.x     Document Type: Article

References (38)

1. Bonnekoh B, Huerkamp C, Wevers A, et al: Up-regulation of keratin 17 expression in human HaCaT keratinocytes by interferon-gamma. J Invest Dermatol 104:58-61, 1995
2. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761-771, 1988
3. Carroll JM, Crompton T, Seery JP, Watt FM: Transgenic mice expressing IFN-gamma in the epidermis have eczema, hair hypopigmentation, and hair loss. J Invest Dermatol 108:412-422, 1997
4. Chen SH, Arany I, Apisarnthanarax N, et al: Response of keratinocytes from normal and psoriatic epidermis to interferon-gamma differs in the expression of zinc-alpha(2)-glycoprotein and cathepsin D. FASEB J 14:565-571, 2000
5. Companjen AR, van der Wel LI, Wei L, Laman JD, Prens EP: A modified ex vivo skin organ culture system for functional studies. Arch Dermatol Res 293:184-190, 2001
6. Davidson A, Diamond B: Autoimmune diseases. N Engl J Med 345:340-350, 2001
7. Erkek E, Karaduman A, Akcan Y, Sokmensuer C, Bukulmez G: Psoriasis associated with HCV and exacerbated by interferon alpha: Complete clearance with acitretin during interferon alpha treatment for chronic active hepatitis. Dermatology 201:179-181, 2000
8. Fah J, Pavlovic J, Burg G: Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem 43:47-52, 1995
9. Fukuyama S, Kajiwara E, Suzuki N, Miyazaki N, Sadoshima S, Onoyama K: Systemic lupus erythematosus after alpha-interferon therapy for chronic hepatitis C: A case report and review of the literature. Am J Gastroenterol 95:310-312, 2000
10. Griffiths CE, Barker JN, Kunkel S, Nickoloff BJ: Modulation of leucocyte adhesion molecules, a T-cell chemotaxin (IL-8) and a regulatory cytokine (TNF-alpha) in allergic contact dermatitis (rhus dermatitis). Br J Dermatol 124:519-526, 1991
11. Hida S, Ogasawara K, Sato K, et al: CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 13:643-655, 2000
12. Jackson M, Howle SEM, Weller RJ, Sabin E, Hunter JAA, McKenzie RC: Psoriatic keratinocytes show reduced stat-1a and IRF activation in response to IFN-γ. FASEB J 13:495-502, 1999
13. de Jong EM, van Vlijmen IM, van Erp PE, Ramaekers FC, Troyanovski SM, van de Kerkhof PC: Keratin 17: A useful marker in anti-psoriatic therapies. Arch Dermatol Res 283:480-482, 1991
14. LaFleur DW, Nardelli B, Tsareva T, et al: Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem 276:39765-39771, 2001
15. Levy DE, Lew DJ, Decker T, Kessler DS, Darnell JE Jr: Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J 9:1105-1111, 1990
16. Livden JK, Nilsen R, Bjerke JR, Matre R: In situ localization of interferons in psoriatic lesions. Arch Dermatol Res 281:392-397, 1989
17. McMurray RW, Elbourne K: Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum 26:689-701, 1997
18. Nardelli B, Zaritskaya L, Semenuk M, et al: Regulatory effect of IFN-kappa, a novel type I IFN, on cytokine production by cells of the innate immune system. J Immunol 169:4822-4830, 2002
19. Nickoloff BJ: The immunologic and genetic basis of psoriasis. Arch Dermatol 135:1104-1110, 1999
20. Pauluzzi P, Kokelj F, Perkan V, Pozzato G, Moretti M: Psoriasis exacerbation induced by interferon-alpha. Report of two cases. Acta Derm Venereol 73:395, 1993
21. Pittau E, Bogliolo A, Tinti A, et al: Development of arthritis and hypothyroidism during alpha-interferon therapy for chronic hepatitis C. Clin Exp Rheumatol 15:415-419, 1997
22. Prens EP, Benne K, van Joost T, Benner R: The autologous mixed epidermal cell-T lymphocyte reaction is elevated in psoriasis: A crucial role for epidermal HLA-DR+/CD1a-antigen-presenting cells. J Invest Dermatol 96:880-887, 1991
23. Recasens M, Aguilera E, Ampurdanes S, et al: Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C. Diabet Med 18:764-767, 2001
24. Rizova H, Nicolas JF, Morel P, et al: The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin. J Dermatol Sci 7:1-13, 1994
25. Rose NR, Bona C: Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 14:426-430, 1993
26. Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T, Tanaka N: Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEES Lett 441:106-110, 1998
27. Schmid P, Itin P, Cox D, McMaster GK, Horisberger MA: The type I interferon system is locally activated in psoriatic lesions. J Interferon Res 14:229-234, 1994
28. Sebok B, Bonnekoh B, Mahrle G: IL-1 alpha-induced expression of ICAM-1 on cultured hyperproliferative keratinocytes: Suppression by antipsoriatic dimethyl-fumarate. Int J Dermatol 33:367-370, 1994
29. Sebok B, Bonnekoh B, Vetter R, Schneider I, Gollnick H, Mahrle G: The antipsoriatic dimethyl-fumarate suppresses interferon-gamma-induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique. Eur J Dermatol 8:29-32, 1998
30. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N: IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19:623-655, 2001
31. Tompkins WA: Immunomodulation and therapeutic effects of the oral use of interferon-alpha: Mechanism of action. J Interferon Cytokine Res 19:817-828, 1999
32. Trepicchio WL, Ozawa M, Walters IB, et al: Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104:1527-1537, 1999
33. Unoki H, Moriyama A, Tabaru A, Masumoto A, Otsuki M: Development of Sjögren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C. J Gastroenterol 31:723-727, 1996
34. Van Der Fits L, Van Der Wel LI, Laman JD, Prens EP, Verschuren MC: Psoriatic lesional skin exhibits an aberrant expression pattern of interferon regulatory factor-2 (IRF-2). J Pathol 199:107-114, 2003
35. Veals SA, Schindler C, Leonard D, et al: Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol Cell Biol 12:3315-3324, 1992
36. Wei L, Debets R, Hegmans JJ, Benner R, Prens EP: IL-1 beta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-gamma up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production. J Pathol 187:358-364, 1999
37. Wollenberg A, Wagner M, Gunther S, et al: Plasmacytoid dendritic cells: A new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 119:1096-1102, 2002
38. Yamamoto T, Katayama I, Nishioka K: Psoriasis and hepatitis C virus. Acta Derm Venereol 75:482-483, 1995